Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

BRIEF-Clovis Oncology Announces Notice Of Allowance For Rucaparib High Dosage Strength Tablet Patent With Expiration In 2035

By: Reuters: Company News
* CLOVIS ONCOLOGY ANNOUNCES NOTICE OF ALLOWANCE FOR RUCAPARIB HIGH DOSAGE STRENGTH TABLET PATENT WITH EXPIRATION IN 2035 Source text for Eikon: Further company coverage:
Related Stocks:
Clovis Oncology Inc
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.